Tempol intake improves inflammatory status in aged mice

  • Yamato Mayumi
    Innovation Center for Medical Redox Navigation, Kyushu University
  • Ishimatsu Ayumi
    Department of Bio-functional Science, Faculty of Pharmaceutical Sciences, Kyushu University
  • Yamanaka Yuuki
    Department of Bio-functional Science, Faculty of Pharmaceutical Sciences, Kyushu University
  • Mine Takara
    Department of Bio-functional Science, Faculty of Pharmaceutical Sciences, Kyushu University
  • Yamada Kenichi
    Department of Bio-functional Science, Faculty of Pharmaceutical Sciences, Kyushu University JST, PRESTO

この論文をさがす

抄録

Oxidative stress is associated with both healthy aging and age-related disease states. In connection with oxidative stress, immunity is also a major component as a result of the chronic, low-grade inflammation associated with the development of tissue aging. Here we show that long-term treatment with the antioxidant tempol extends life-span in mice. Tempol-treated mice exhibited a reduction in mortality at 20 months. Tempol drinking did not have any effect on body weight, amount of visceral adipose tissue, or plasma biochemical parameters in aged mice. Body temperature of aged control mice (which drank only water) was significantly lower than young mice, but this reduction of body temperature was partially restored in aged mice which drank tempol. Plasma thiobarbituric acid-reactive substances and C-reactive protein were significantly increased in the control aged mice compared with young mice, but levels of both were normalized by tempol drinking. One of the endogenous antioxidants, ascorbic acid, was significantly increased in the plasma of mice which consumed tempol. The proportion of CD4 lymphocytes in the blood of aged tempol-treated mice was partially increased in comparison to aged control mice. These results suggest that the reduction of mortality by tempol is due to amelioration of chronic inflammation and improved function of the immune system through antioxidant effects.

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (30)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ